Research Radartracking 1,316 published studies · 343 human · 8 safety signals · 43 clinical trials · 44 cancer pages · updated Aug 2026Open the Research Map →

Research Radar

New PubMed studies on repurposed drugs and natural compounds in cancer — summarized in plain language and reviewed by a person before posting.

How to read this page. These studies are automatically collected from PubMed and summarized by AI from the abstract, then reviewed by a human before publishing. Each summary describes only what that study reported — most are early lab, animal, or small human studies, and findings often conflict. This is educational information, not medical advice, and not a recommendation to take anything. Always talk with your oncologist.
Topic tags. Each study is filed under its main topic. Anticancer studies are the default; these tags flag the other dimensions:
Safety — Safety & interactionsAbsorption (PK) — How it's absorbed (PK)Formulation — Formulation & deliverySupportive care — Symptom & supportive careMetabolism — Metabolism & pathwaysTrial — Clinical trialMechanism — Biomarker & mechanism
Showing studies that mention “ovarian epithelial carcinoma”.
1 of 200 studies
Human · observationalMechanismReported positiveLimited evidenceTier 3 · early humann = 381

FOXA1 expression and its association with mucin expression and KRAS mutation in ovarian mucinous tumors: implications for tumor progression and differentiation

Virchows Archiv : an international journal of pathology · Sep 2025

ovarian mucinous tumorsovarian epithelial carcinomas

The authors examined FOXA1 protein expression by immunohistochemistry and KRAS mutation status across normal/benign ovarian tissues, mucinous ovarian tumors, and other ovarian epithelial carcinomas (total n=381). FOXA1 was commonly expressed in mucinous tumors and its expression correlated with MUC2; KRAS mutations increased with malignancy but were relatively enriched in FOXA1-negative cystadenomas. The authors propose that co-occurrence of KRAS mutation and FOXA1 expression may relate to tumor progression and intestinal-type differentiation.

Reported effects: FOXA1 expression in cystadenomas 73.6% · FOXA1 expression in borderline tumors 91.4% · +7 more

Key findings
  • FOXA1 expression was significantly associated with mucinous histology in ovarian epithelial carcinomas (P < 0.001).
  • In mucinous tumors, FOXA1 was expressed in 73.6% of cystadenomas, 91.4% of borderline tumors, 100% of borderline tumors with intraepithelial carcinomas, and 87.5% of carcinomas.
  • MUC2 expression progressively increased from mucinous cystadenomas to borderline tumors (P < 0.050) and significantly correlated with FOXA1 expression (P = 0.024).
  • The prevalence of KRAS mutations tended to increase with the malignancy of mucinous tumors (P < 0.050).
  • KRAS mutations were significantly enriched in FOXA1-negative cystadenomas compared with FOXA1-positive cystadenomas (P < 0.050).
  • A stepwise increase was noted in the percentage of both KRAS mutations and FOXA1 expression from cystadenoma to carcinoma.
Limitations: Observational analysis of tumor specimens only (no functional or mechanistic experiments reported).; No clinical outcome or survival data were reported to link findings to prognosis.; Causality between FOXA1 expression, KRAS mutation, and tumor progression or differentiation cannot be established from the methods described..

AI summary of the abstract, human-reviewed · Jul 2026. Describes what this study reported, not medical advice. View on PubMed